Category Archives: healthcare

Rise in IPOs Eases Pharma's Investment Woes

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
Also posted in Biotech, Deals, Global | Tagged , , , , , | Leave a comment

Physicians Won’t Change Their Practices Without Worthwhile Incentives

By Mark Wagar. (This blog first appeared on Managed Healthcare Executive.) There is more collaboration than ever between payers and providers in the drive to provide high-quality, cost-effective care to diverse populations across the United States. According to a January 2014 Centers for Medicare and Medicaid Services (CMS) report, the accountable care organization (ACO) model is […]
Also posted in Guest Blog, Regulatory | Tagged , , , , , , | Leave a comment

Things Looking Up for Obamacare, But New HHS Chief Faces Tough 2015

This blog previously ran on Managed Healthcare Executive. The Obama administration received a substantial amount of good news last month. Not only did 8 million individuals enroll in qualified health plans, millions more joined Medicaid or obtained coverage through private markets. Additionally, health reform will cost $100 billion less than anticipated, according to the Congressional […]
Also posted in Op-Ed, Regulatory | Tagged , , , , | Leave a comment

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Also posted in Biotech, Guest Blog, leadership, Legal, Market Access, Strategy | Tagged , , , , , , , | 2 Comments

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, leadership, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment
  • Categories

  • Meta